Efficacy and Safety of Nerinetide in Participants With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy Excluding Thrombolysis
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 850 participants.
Also called NCT04462536
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 850 participants
- Sponsor
- Registry
-
NCT04462536
-
- Other papers using this trial's data
- Efficacy and safety of nerinetide in acute ischaemic stroke in patients undergoing endovascular thrombectomy without previous thrombolysis (ESCAPE-NEXT): a multicentre, double-blind, randomised controlled trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Canada, Germany, Italy, Netherlands, Norway, Singapore, Switzerland
- Registry status
- Completed
Technical summary
Registry record NCT04462536. Randomized; quadruple masking; primary purpose treatment. Start 2020-12-06 (actual); primary completion 2023-08-31 (actual). Results posted on 2025-06-22.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Nerinetide in Participants With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy Excluding Thrombolysis
- Acronym
- ESCAPE-NEXT
- Condition
- Stroke, Acute
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Nerinetide
- Lead sponsor
- NoNO Inc.
- Collaborator
- University of Calgary
Record details
- Record id
cardio:ct-nct04462536- Content hash
d7d484057c23b4d33c1b12cbe0dc52b64f462fb78df632e2206a55e2dd3accde